terminated in patients who had a successful immune response to antiretroviral therapy. [2] [3] [4] The pharmacokinetic interaction between itraconazole and NNRTIs has been documented in human volunteers and in histoplasmosis case reports. In the study by Huet and colleagues 5 -cited by Schwartz and Wasserman-efavirenz was associated with a 20-50% reduction in plasma itraconazole concentrations, but was also associated with substantial increases in the concentration of its active metabolite hydroxyitraconazole, which has similar antifungal activity. In the study by Koo and coworkers, 6 itraconazole concentrations were inversely correlated with urine histoplasma antigen levels in a patient who was clinically cured. None of the studies showed a correlation between low blood itraconazole concentrations and clinical response or relapse.
Well designed pharmacokinetic and pharmacodynamics studies are required to evaluate the association between itraconazole exposure and response in the treatment of endemic mycoses to assess the therapeutic range of itraconazole, and to further investigate interactions between itraconazole and antiretrovirals. Of note, such analyses are in progress for a trial in Vietnam 7 comparing itraconazole and amphotericin B as an initial treatment for HIV-associated talaromycosis. All patients with HIV started treatment with efavirenz and received the standard maintenance dose of itraconazole of 200 mg daily. The overall relapse rate was low at 4·0%, and 1·5% in patients who received a course of amphotericin B before itraconazole. 7 We do agree that therapeutic drug monitoring for itraconazole 8 and protease and integrase inhibitor-based antiretroviral therapy are appropriate strategies. However, at present we would maintain that the evidence is insufficient to change the current practice for consolidation and maintenance itraconazole dosing 
Author's reply
We thank Ilan S Schwartz and Sean Wasserman for their interest in our paper on the management of HIV-associated endemic mycoses. 1 Schwartz and Wasserman rightly express concern regarding the known drug-drug interaction between itraconazole and nonnucleotide reverse transcriptase inhibitors ( tuberculosis control programmes for migrants. Addressing them requires detailed data from programmes, 6 including data linkage between pre-entry screening programmes, 7 postmigration latent tuberculosis infection screening and treatment programmes, and surveillance of active tuberculosis diagnoses.
Programmes need to ensure access to screening, promote treatment uptake in patients with diagnosed latent tuberculosis infection, and provide effective support for adherence to treatment, in ways that are culturally sensitive and cost-effective. Uncertainty in the effectiveness of latent tuberculosis infection treatment regimens 8 causes uncertainty in the expected impact and cost-effectiveness of screening and treatment programmes. Record linkage of large, detailed datasets from such screening programmes and surveillance of active tuberculosis diagnoses will be essential for assessing and optimising the impact of the programmes. Finally, it is important to monitor the epidemiology of tuberculosis and the performance of control programmes at the local level to ensure appropriate allocation of resources and equitable access to care. 5 PJW has received research funding from Otsuka SA for a retrospective study of multidrug-resistant tuberculosis treatment in several eastern European countries. IA and ACH co-chaired the National Institute for Health and Care Excellence tuberculosis guideline development group, which considered evidence on testing and treatment of latent tuberculosis in migrant groups. RWA declares no competing interests. PJW thanks the UK National
Post-migration follow-up of migrants at risk of tuberculosis
In recent Correspondence about the screening and treatment of latent tuberculosis infection in migrants who had moved from countries with a high tuberculosis burden to low-burden countries, Kayvan Bozorgmehr 1 reported that asylum seekers in Germany from Somalia and Iraq had very different prevalences of latent infection. He commented that "Many studies on effectiveness of tuberculosis screening treat migrants as homogenous, neglecting that this population is socially constructed and highly heterogeneous", citing our study 2 as one of the examples.
In fact, we did not treat our study cohort as homogeneous: we presented analysis considering age, sex, visa category (students, settlement and dependants, work, working holiday, family reunion, other), and tuberculosis prevalence of the country of origin, and found that there were significant differences in tuberculosis risk associated with the last two variables. 2 This complements earlier work on the yield of latent tuberculosis infection screening in England, 3,4 which informed the new national screening programme in England.
We agree with Bozorgmehr that collection of detailed data is important "to develop and assess screening programmes that account for the heterogeneity in migrant populations". 1 We would like to highlight that in addition to latent tuberculosis infection prevalence in different migrant groups, several other important considerations are related to the effectiveness, cost-effectiveness, and equity 3-5 of
